200 related articles for article (PubMed ID: 20345925)
1. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.
Mann A; Tyndale RF
Eur J Neurosci; 2010 Apr; 31(7):1185-93. PubMed ID: 20345925
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.
Chattopadhyay M; Chowdhury AR; Feng T; Assenmacher CA; Radaelli E; Guengerich FP; Avadhani NG
J Biol Chem; 2019 Jun; 294(26):10336-10348. PubMed ID: 31113867
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.
Bajpai P; Sangar MC; Singh S; Tang W; Bansal S; Chowdhury G; Cheng Q; Fang JK; Martin MV; Guengerich FP; Avadhani NG
J Biol Chem; 2013 Feb; 288(6):4436-51. PubMed ID: 23258538
[TBL] [Abstract][Full Text] [Related]
4. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
5. The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.
Singh S; Singh K; Patel DK; Singh C; Nath C; Singh VK; Singh RK; Singh MP
Rejuvenation Res; 2009 Jun; 12(3):185-97. PubMed ID: 19594327
[TBL] [Abstract][Full Text] [Related]
6. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.
Matoh N; Tanaka S; Takehashi M; Banasik M; Stedeford T; Masliah E; Suzuki S; Nishimura Y; Ueda K
Gene Expr; 2003; 11(3-4):117-24. PubMed ID: 14686785
[TBL] [Abstract][Full Text] [Related]
8. Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells.
Tasaki Y; Omura T; Yamada T; Ohkubo T; Suno M; Iida S; Sakaguchi T; Asari M; Shimizu K; Matsubara K
Brain Res; 2010 Jul; 1344():25-33. PubMed ID: 20452332
[TBL] [Abstract][Full Text] [Related]
9. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
10. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
11. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6.
Kalgutkar AS; Zhou S; Fahmi OA; Taylor TJ
Drug Metab Dispos; 2003 May; 31(5):596-605. PubMed ID: 12695348
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization.
Gilham DE; Cairns W; Paine MJ; Modi S; Poulsom R; Roberts GC; Wolf CR
Xenobiotica; 1997 Jan; 27(1):111-25. PubMed ID: 9041683
[TBL] [Abstract][Full Text] [Related]
13. The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells.
Zhang D; Zhang JJ; Liu GT
Neuropharmacology; 2007 Feb; 52(2):423-9. PubMed ID: 17055540
[TBL] [Abstract][Full Text] [Related]
14. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients.
Mann A; Miksys SL; Gaedigk A; Kish SJ; Mash DC; Tyndale RF
Neurobiol Aging; 2012 Sep; 33(9):2160-71. PubMed ID: 21958961
[TBL] [Abstract][Full Text] [Related]
15. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
Zhou SF; Liu JP; Lai XS
Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP
Wu KC; Liou HH; Lee CY; Lin CJ
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):157-173. PubMed ID: 29679389
[TBL] [Abstract][Full Text] [Related]
17. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.
Chauret N; Dobbs B; Lackman RL; Bateman K; Nicoll-Griffith DA; Stresser DM; Ackermann JM; Turner SD; Miller VP; Crespi CL
Drug Metab Dispos; 2001 Sep; 29(9):1196-200. PubMed ID: 11502727
[TBL] [Abstract][Full Text] [Related]
18. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.
Fang J; Zuo D; Yu PH
Psychopharmacology (Berl); 1995 Oct; 121(3):373-8. PubMed ID: 8584620
[TBL] [Abstract][Full Text] [Related]
20. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
